Thursday, March 24, 2005

Ingen Technologies Exhibits Product Line at the American Academy of Neurology

For Immediate Release:

Calimesa, CA- March 24, 2005 for 8:15AM EST: Ingen Technologies (OTC: IGTN), a medical device manufacturer and service provider for medical and consumer markets, announced today that they will exhibit the Secure Balance™ product lines at the annual meeting of the American Academy of Neurology. The exhibit begins April 11th through the 14th, 2005 at the Miami Beach Convention Center.

Jacob Green, MD, President and Founder of the Southeastern Neuroscience Institute stated: “The American Academy of Neurology has 14,000 members. At least 2,000 shall arrive in Miami and be there to take courses and find out what the newest equipment is and how to provide better services for patient care. The Secure Balance™ product line is superior to any other product line in the industry, and it is exclusively endorsed by our Foundation and the American Academy of Balance Medicine.”

Jacob Green, MD is lecturing at a scheduled workshop for the Secure Balance™ customers. “There are 20 physicians attending this workshop on April 1st and 2nd in Jacksonville. 15 of the physicians are planning to make a purchase after the workshop.” Said Dr. Green. This represents an additional $795,000 in revenues for the company.

EXCERPTS FROM AAN SPECIAL ARTICLE ASSESSMENTS: ELECTRONYSTAGMOGRAPHY

A REPORT OF THE THERAPEUTICS AND TECHNOLOGY ASSESSMENT SUBCOMMITTEE PUBLISHED IN NEUROLOGY 1996 (46:1763-1766).

Executive summary page 1705 quotes the following, "VNG is considered an established vestibular ocular function test, which is both safe and effective." This review of electronystagmography based on class 3 evidence.

A REVIEW OF THE SPECIAL ARTICLE ASSESSMENT; VESTIBULAR TESTING TECHNIQUES IN ADULTS AND CHILDREN, REPORT OF THERAPEUTIC AND TECHNOLOGY ASSESSMENT SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY, PUBLISHED NEUROLOGY 2000 (55:1431-1441).

"Infrared Video Nystagmography" is a method of determining eye movements, which utilizes infrared cameras to detect movements of the eyes. These eye movements are recorded by EOG. Rotational head testing does not depend on effectiveness of thermal energy transfer of the middle ear (as opposed to calorics). Rotational testing can be done either in a passive fashion or active with a rotational chair. It is noted that there is a high degree of correlation in the ("passive") head movement and with the rotational chairs ("active"), which are especially in good in patients with bilateral disease and those with ototoxicity.

The overall assessment of vestibular responses has been that it is an "acceptable technique."

The report says "quantitative vestibular testing, whether caloric or rotational, may be used as a confirmatory test to clinical history and examination when the symptoms are suggestive of vestibular dysfunction.

The above AAN Scientific Affairs committee articles are formally published statements to the American Academy of Neurology showing that this VNG technology is safe and effective, but requires individuals (ACPs) who will be trained and knowledgeable in their use.

Scott Sand, CEO & Chairman of Ingen Technologies, stated, “ It is a prestigious honor to support the American Academy of Neurology. This is the fastest growing medical product for this industry. With an increasing elderly population in the United States, the neurologist can provided balance and fall prevention services to their patients at a reasonable cost. With use of the Secure Balance™ products, helping patient’s regain their balance also substantially reduces Medicare costs for fall related injuries. These fall related injuries are prevented through the use of the Secure Balance™ products and therapy programs. More important is that the patient has a more healthier and active lifestyle.”

About Ingen Technologies

Ingen Technologies (OTC: IGTN), in business since 1999, is a medical device manufacturer and service provider for medical and consumer markets both domestic and abroad. Currently increasing revenues are generated from the Company’s Secure Balance™ program; a medical product line for physicians and hospitals that provide patient services for Balance & Fall Prevention programs. The OxyALERT™ is another product line that has an issued US Patent and is a proprietary technology. This product is the second generation development of the Company’s initial BAFI™ product; a medical safety device that provides wireless and remote monitoring of oxygen delivery systems for patients and small aircraft. Using the same patented and proprietary technology, the Company has the GasAlert™ product; a device that interfaces between any gas line and accessory, such as a water heater, dryer, stove or heater, to detect leaks. This is a mass consumer item expected to go to market in 2005.

“Our team of professionals has developed medical products for the growing elderly population. These products are superior to any of our competition and they allow effective medical product availability to seniors, and at the same time the demand allows for a steady growth in sales and profits”; said Scott Sand, CEO & Chairman of Ingen Technologies.

For more information, visit www.ingen-tech.com

Investor Relations Contact: Scott R. Sand, C.E.O & Chairman
Ingen Technologies, Inc.
285 E. County Line Road
Calimesa, CA 92320
800-259-9622
951-675-3266
800-777-1186 FAX
[email protected]

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements that are made pursuant to “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Download this article in PDF format: IGTNAAN032305d1.pdf